- Home
- BMO vs BMY Comparison
BMO vs BMY Comparison
Compare BMO & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BMO | BMY |
|---|---|---|
| Founded | 1817 | 1887 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 127.2B | 113.5B |
| IPO Year | 2014 | 2006 |
Fundamental Metrics
Financial Performance| Metric | BMO | BMY |
|---|---|---|
| Price | $170.49 | $61.31 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 15 | 28 |
| Target Price | ★ $168.51 | $65.25 |
| AVG Volume (30 Days) | 429.7K | ★ 11.9M |
| Earning Date | 12-02-2026 | 10-29-2026 |
| Dividend Yield | 2.90% | ★ 4.10% |
| EPS Growth | N/A | ★ 178.46 |
| EPS | N/A | ★ 2.93 |
| Revenue | N/A | ★ $48,194,000,000.00 |
| Revenue This Year | $8.26 | $3.54 |
| Revenue Next Year | $4.76 | N/A |
| P/E Ratio | ★ $17.46 | $21.05 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $119.84 | $42.52 |
| 52 Week High | $187.22 | $68.64 |
Technical Indicators
Market Signals| Indicator | BMO | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 55.52 | 50.09 |
| Support Level | $166.96 | $59.91 |
| Resistance Level | $177.40 | $62.77 |
| Average True Range (ATR) | 2.61 | 1.81 |
| MACD | 1.03 | 0.45 |
| Stochastic Oscillator | 95.00 | 68.28 |
Price Performance
Historical ComparisonAbout BMO Bank Of Montreal
Bank of Montreal is a diversified financial services provider based in North America with over CAD 1.47 trillion in assets by the end of fiscal 2025. BMO operates four business segments: Canadian personal and commercial banking, US personal and commercial banking, wealth management, and capital markets. About 60% of BMO's earnings are generated in Canada and 40% in the US.
About BMY Bristol-Myers Squibb Company
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.